Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Lymphoma 7Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, T-Cell, Cutaneous 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1

Interventions

pembrolizumab 2durvalumab 1atezolizumab 1advexin 1Nivolumab 1Injections, Subcutaneous 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × durvalumab × Lymphoid × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡